34 累计需求单数
¥1,355,097.0 累计需求金额
0 违规次数

阿斯利康公司需要一种弥漫性巨大B细胞淋巴瘤的临床相关发展模型

悬赏
未托管赏金
¥90000.00
  1. 发布需求
  2. 药智客交稿
  3. 任务主选稿中
  4. 验收与付款
  1. 任务结束
任务结束
交易模式:
单人中标
赏金分配:
一人独享赏金,¥90000
具体要求:
弥漫性大B细胞淋巴瘤(DLBCL)是一种最常见的非霍奇金淋巴瘤,诊断病例在美国约占淋巴瘤的30%。它是一种特异质性疾病。由于临床多样性和复杂性,又有新的突变在某些难治性患者身上被发现。阿斯利康需要创建一种弥漫性巨大B细胞淋巴瘤的合适的临床模型。 具体链接在:https://www.innocentive.com/ar/challenge/9933016 AstraZeneca Challenge: Developing Clinically-Relevant Models for Diffuse Large B Cell Lymphoma (DLCBL) TAGS: AstraZeneca, Physical Sciences, Life Sciences, Nature, Requests for Partners and Suppliers, Chemistry, RTP AWARD: See details | DEADLINE: 6/02/15 | ACTIVE SOLVERS: 9 | POSTED: 3/04/15 Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and accounts for up to 30% of newly diagnosed cases in the United States. It is a heterogeneous disease which in part appears to be driven by chronic activation of key survival pathways. A limited number of DLBCL cell lines are available, however there are gaps, and specific patient subtypes are not represented. To add to the complexity of clinical diversity, new mutations are being identified in certain treatment-resistant patients. AstraZeneca is interested in innovative proposals to create suitable preclinical models of DLBCL. This is a Reduction-to-Practice Challenge that requires a written proposal and experimental proof-of-concept data (and/or sample delivery). The Challenge has a special award structure. Whether creating a model for DLBCL or a model of acquired resistance to ibrutinib, up to $10,000 will be designated for solutions that highlight novel technologies to generate in vitro cell lines, whereas up to $25,000 will be awarded for submissions that successfully utilize patient-derived tissues.
2015-03-13 14:16
0条新稿件,点击看看
还没有人交稿哦!
赶快点击交稿吧~

当前为付费需求,赏金分配方式:一人独享赏金。

任务主在众多备选稿件中选择最满意的稿件,支付赏金。

托管赏金,保障各方权益:

任务主把所发需求的悬赏金托管到药智网指定账户,以激发众多药智客的参与热情,保障任务主尽快征集到满意稿件;

同时,赏金托管也是为了保障参与挑战的药智客的正当权益。

流程说明:

发布需求

点击“发布需求”按钮,按照流程引导,将需求详情、具体要求描述清楚,发布到药智网的药智汇平台。

托管赏金

为征集到满意稿件,任务主须做好“赏金预算”,并将赏金托管到药智网指定账户,打消药智客的顾虑,激励药智客积极参与需求挑战。

药智客参与

任务主托管赏金后,所发布的需求显示“赏金已托管”字样。只有托管了悬赏金的需求,能够鼓舞众多的药智客参与,获取到满意的稿件!

选择满意稿件

任务主在众多参与者提交的稿件中,选择符合任务主需求的稿件。再通过互动,选择任务主最满意的稿件,并确定其为中标稿件。

验收与付款

中标稿件提交任务主验收。任务主在验收/验证期内,完成验收/验证工作。对合格稿件,通知药智网支付佣金。

评价

双方可以针对本次交易各自的表现进行评价,评价结果将影响各自的信用度和能力值。

类似的需求

    加载数据中...

该需求者还有这些需求

    加载数据中...

推荐需求

    加载数据中...
感兴趣,就投稿吧!投的越早,中标几率就越大! 收藏
挖掘医药数据,分享医药情报
扫一扫,关注药智数据公众号

2014 药智再发力 我们换装了!!

为了让您有更好的体验,药智对用户体系和产品进行了全新升级!

我要看看